secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001493152-25-021418
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi presents positive preclinical data on CLD-401 at SITC; IND filing expected by end 2026
--------------------------------------------------------------------------------

- CLD-401 protected from immune clearance and replicates specifically in tumor cells after systemic administration.
- Systemic CLD-401 achieves tumor IL-15 superagonist levels comparable to localized Anktiva dosing, with minimal systemic exposure.
- IND-enabling studies ongoing; IND submission expected by end of 2026.
- Company actively seeking strategic partnerships to accelerate clinical development.
- Investor day held at SITC featuring experts Dr. Zamarin (Mount Sinai) and Dr. Wrangle (MUSC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225021418/0001493152-25-021418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225021418/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer